HR 2666 · 118th Congress · Health

Medicaid VBPs for Patients Act

Introduced 2023-04-18· Sponsored by Rep. Guthrie, Brett [R-KY-2]· House

Bill Progress

Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Placed on the Union Calendar, Calendar No. 768.(2024-12-19)

Plain Language Summary

[AI summary unavailable — showing source text] Medicaid VBPs for Patients Act or the MVP Act This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. ( Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.) The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes. Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to establish a program under which state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements. The bill's changes terminate five…

Summarized by Claude AI · Non-partisan · For informational purposes only

CBO Cost Estimate

Congressional Budget Office

H.R. 2666, Medicaid VBPs for Patients Act

Dec 18, 2024

As reported by the House Committee on Energy and Commerce on November 18, 2024

Full CBO report ↗

Official non-partisan budget analysis by the Congressional Budget Office

Cosponsors (20)

12 Democrats8 Republicans